Rhythm Pharma's Imcivree generated $92.1 million in Q3; its estimated $8.25 billion market cap exceeds 20 times estimated 2026 revenue. I rate RYTM stock as Hold.
Rhythm Pharmaceuticals rose 3.6% as traders cited an alert that Eli Lilly submitted a rival bid near $150 per share plus a contingent value right.
Eli Lilly (LLY) signs an exclusive cancer-drug licensing deal with Stipple Bio for an equity investment, upfront cash, and up to $5.9B in milestones. Read more here.
Lilly found no unauthorized access to its own systems, a person familiar with the matter said. Extortion group n0n claims to hold patient and prescriber data.
Lilly found no unauthorized access to its own systems, a person familiar with the matter said. Extortion group n0n claims to hold patient and prescriber data.
Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.
Every weekday, the Investing Club releases the Homestretch; an actionable afternoon update just in time for the last hour of trading.
Eli Lilly and Co (NYSE:LLY) has agreed to acquire privately held biotechnology company Calytrix Bio for up to $1.5 billion in cash, expanding its efforts to develop treatments for rare blood disorders and strengthen its presence in haematology. Under the definitive agreement, Calytrix...
Here are Monday's biggest calls on Wall Street.
CVS Health's Aetna claims analysis finds GLP-1s priced below $350 a month could yield net savings for payors through reduced health care use. Read more here.
Top-rated Eli Lilly, known for its blockbuster GLP-1 weight loss and diabetes drugs, hit a new high and led 9 new to best stock lists.
Eli Lilly breaks ground on a $3.5B Pennsylvania manufacturing center for next-generation weight loss treatments, expected to open in 2031. Read more here.
This is the newest page. Registered accounts read further back.